McNeil willing to pay 7% royalties on ibuprofen sinus combos, minus development costs.
This article was originally published in The Tan Sheet
Executive Summary
McNEIL WILLING TO PAY ROYALTIES ON IBUPROFEN-COUGH/COLD COMBO MINUS COST of developing the NDA for the 200 mg ibuprofen/30 mg pseudoephedrine combination in Motrin IB Sinus and Sine-Aid IB products, the J&J subsidiary said in a brief filed with the Delaware U.S. district court on May 24. Motrin IB Sinus, manufactured by McNeil, is sold by Upjohn, the other defendant in the suit.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning